The cure rate for children with neuroblastoma is unacceptable, making it imperative that new therapies are developed. Dr. Bosse's laboratory is focused on discovering and developing new neuroblastoma cell surface immunotherapeutic targets. Along with his colleagues, Dr. Bosse's aim is to capitalize on the robust differential expression of these molecules with immune-based therapies and also define their mechanisms of overexpression and roles in tumorigenesis.
Dr. Barret's research program focuses on immune function of children with cancer. His research involves investigating possible immune deficiencies that result in children developing cancer and developing immune-based therapies for childhood cancer.
Notable awards, new autism initiatives, and a novel approach to managing sickle cell disease are all part of this week's roundup of research news. As Children's Hospital of Philadelphia experts made waves at the American Academy of Pediatrics (AAP) National Conference in Chicago, our local Philadelphia Eagles launched a new commitment to support autism research at CHOP and neighboring institutions
The investigators, Stephen A. Grupp, MD, PhD and Carl H. June, MD, engineered T cells - the workhorses of the immune system, which recognized and attack invading disease cells - to selectively kill another type of immune cell called B cells, which had become cancerous.
According to new research from The Children's Hospital of Philadelphia and the University of Pennsylvania,
The Barrett Lab studies the immune function of children with cancer. This research program takes two paths: investigating possible immune deficiencies that result in children developing cancer and developing immune-based therapies for childhood cancer.
The Cancer Pharmacology Laboratory supports clinical trials of new mechanistically targeted and immune-based anticancer drugs by conducting pre-clinical and clinical pharmacology studies of the agents. The lab also studies conventional anticancer drugs to develop more rational and effective dosing methods, and the lab team is developing circulating biomarkers of organ function, drug toxicity, and tumor burden as clinical trial endpoints.